請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50094完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳兆勛(Chao-Hsun Chen) | |
| dc.contributor.author | Hsu-Tsung Huang | en |
| dc.contributor.author | 黃昫璁 | zh_TW |
| dc.date.accessioned | 2021-06-15T12:29:34Z | - |
| dc.date.available | 2021-08-24 | |
| dc.date.copyright | 2016-08-24 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-08-05 | |
| dc.identifier.citation | 1. 衛生福利部國民健康署. Available from: http://www.mohw.gov.tw/news/531349778
http://www.hpa.gov.tw/BHPNet/Web/HealthTopic/TopicArticle.aspx?No=201312230001&parentid=200712250033. 2. 臺北市立聯合醫院癌症防治研究發展中心. Available from: http://website.tpech.gov.tw/cancer/%E7%99%8C%E7%97%87%E9%A0%90%E9%98%B2%E8%88%87%E7%AF%A9%E6%AA%A2/%E4%B9%B3%E7%99%8C%E7%B0%A1%E4%BB%8B.html. 3. 三軍總醫院-血液腫瘤科. Available from: http://wwwu.tsgh.ndmctsgh.edu.tw/hem/hema_oncology/cancer_breast.htm. 4. Group, S.C.H.; Available from: https://www.southerncross.co.nz/AboutTheGroup/HealthResources/MedicalLibrary/tabid/178/vw/1/ItemID/41/Breast-cancer-symptoms-diagnosis-treatment.aspx. 5. 台灣乳癌防治基金會. Available from: http://www.breastcf.org.tw/index.php/knowledge-base/knowing-breast-cancer-and-diagnostic. 6. Holliday, D.L. and V. Speirs, Choosing the right cell line for breast cancer research. Breast Cancer Res, 2011. 13(4): p. 215. 7. Goldhirsch, A., et al., Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology, 2011: p. mdr304. 8. Yanagawa, M., et al., Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC research notes, 2012. 5(1): p. 376. 9. Chekhun, S., et al., Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. Experimental oncology, 2013(35,? 3): p. 174-179. 10. 陳虹瑋 and 張家靖, 癌症標靶材料作用於細胞與分子機制之探討: 1. 多光子趨動標靶化奈米鑽石誘發癌細胞死亡之機制; 2. anti-CEACAM6 與 anti-HER-2 單一抗原結合功能區抗體於乳癌標靶治療之研究. 2010. 11. Han, D., et al., Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway. Oncotarget, 2015. 6(38): p. 40907. 12. 馬易世, 大黃粗萃物與其主成分大黃素對於人類大腸直腸癌細胞株細胞凋亡之研究. 2013. 13. 林俐伶, 二十二碳六烯酸和亞麻油酸抑制苯二甲酸誘發 MCF-7 人類乳癌細胞中基質金屬蛋白酶-9 表現機制之探討. 2011. 14. Palumbo, J.S., et al., Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cells. Blood, 2005. 105(1): p. 178-185. 15. Schroeder, A., et al., Treating metastatic cancer with nanotechnology. Nature Reviews Cancer, 2012. 12(1): p. 39-50. 16. van der Pluijm, G., Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone, 2011. 48(1): p. 37-43. 17. Mathias, R.A. and R.J. Simpson, Towards understanding epithelial–mesenchymal transition: A proteomics perspective. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2009. 1794(9): p. 1325-1331. 18. 李卫东 and 花寶金, 肿瘤微环境中的炎性机制与肿瘤转移. 国际肿瘤学杂志, 2011. 38(12): p. 911-913. 19. Ou, K.-L. and H. Hosseinkhani, Development of 3D in vitro technology for medical applications. International journal of molecular sciences, 2014. 15(10): p. 17938-17962. 20. Mikami, S., et al., Invasion and metastasis of renal cell carcinoma. Medical molecular morphology, 2014. 47(2): p. 63-67. 21. Mohamed, M.M. and B.F. Sloane, Cysteine cathepsins: multifunctional enzymes in cancer. Nature Reviews Cancer, 2006. 6(10): p. 764-775. 22. Bi, M.-C., et al., Non-lethal levels of zeaxanthin inhibit cell migration, invasion and secretion of MMP-2 via NF-κB pathway in cultured human uveal melanoma cells. 23. Prat, A. and C.M. Perou, Deconstructing the molecular portraits of breast cancer. Molecular oncology, 2011. 5(1): p. 5-23. 24. Schnitt, S.J., Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathology, 2010. 23: p. S60-S64. 25. 台灣癌症防治網. Available from: http://www.tccf.org.tw/old/magazine/maz38/m8.htm. 26. 和信治癌中心醫院. Available from: http://www.kfsyscc.org/cancer/breast-cancer/therapy/hormone/. 27. Itoh, T., et al., Experimental metastasis is suppressed in MMP-9-deficient mice. Clinical & experimental metastasis, 1999. 17(2): p. 177-181. 28. Curran, S. and G.I. Murray, Matrix metalloproteinases in tumour invasion and metastasis. The Journal of pathology, 1999. 189(3): p. 300-308. 29. Vincenti, M.P. and C.E. Brinckerhoff, Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis research, 2002. 4(3): p. 157-164. 30. Heo, D.S., et al., Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients. Oncology reports, 2014. 31(4): p. 1567-1572. 31. Mehner, C., et al., Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget, 2014. 5(9): p. 2736-2749. 32. Di Fruscia, P., et al., The Discovery of a Highly Selective 5, 6, 7, 8‐Tetrahydrobenzo [4, 5] thieno [2, 3‐d] pyrimidin‐4 (3H)‐one SIRT2 Inhibitor that is Neuroprotective in an in vitro Parkinson’s Disease Model. ChemMedChem, 2015. 10(1): p. 69-82. 33. Haery, L., R.C. Thompson, and T.D. Gilmore, Histone acetyltransferases and histone deacetylases in B-and T-cell development, physiology and malignancy. Genes & cancer, 2015. 6(5-6): p. 184. 34. Ito, K. and I.M. Adcock, Histone acetylation and histone deacetylation. Molecular biotechnology, 2002. 20(1): p. 99-106. 35. Albani, D., et al., The SIRT1 promoter polymorphic site rs12778366 increases IL-6 related human mortality in the prospective study “Treviso Longeva (TRELONG)”. International journal of molecular epidemiology and genetics, 2015. 6(1): p. 20. 36. Markozashvili, D., V. Ribrag, and Y.S. Vassetzky, Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Investigational new drugs, 2015. 33(6): p. 1280-1291. 37. Sack, M.N. and T. Finkel, Mitochondrial metabolism, sirtuins, and aging. Cold Spring Harbor perspectives in biology, 2012. 4(12): p. a013102. 38. Nakagawa, T. and L. Guarente, Sirtuins at a glance. Journal of cell science, 2011. 124(6): p. 833-838. 39. Majmundar, A.J., W.J. Wong, and M.C. Simon, Hypoxia-inducible factors and the response to hypoxic stress. Molecular cell, 2010. 40(2): p. 294-309. 40. Lim, J.-H., et al., Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α. Molecular cell, 2010. 38(6): p. 864-878. 41. Wu, Y. and B.P. Zhou, Inflammation: a driving force speeds cancer metastasis. Cell cycle, 2009. 8(20): p. 3267-3273. 42. Li, X. and N. Kazgan, Mammalian sirtuins and energy metabolism. Int J Biol Sci, 2011. 7(5): p. 575-587. 43. Pandey, K.B. and S.I. Rizvi, Plant polyphenols as dietary antioxidants in human health and disease. Oxidative medicine and cellular longevity, 2009. 2(5): p. 270-278. 44. Lund, K.C. and T. Pantuso, Combination effects of quercetin, resveratrol and curcumin on in vitro intestinal absorption. Journal of Restorative Medicine, 2014. 3(1): p. 112-120. 45. Bureau, G., F. Longpré, and M.G. Martinoli, Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. Journal of neuroscience research, 2008. 86(2): p. 403-410. 46. 黃梓柔 and 陳志杰, 天然抗氧化物之經皮輸藥系統研究: 以白藜蘆醇及大豆異黃酮為例. 2009. 47. Shu, Y., et al., [Determination of the contents of resveratrols and piceids in wines by high performance liquid chromatography with solid phase extraction]. Se pu= Chinese journal of chromatography/Zhongguo hua xue hui, 2005. 23(1): p. 88-91. 48. 安梅, 周瑾, and 陈晓宇, 白藜芦醇药理学作用的研究进展. 肿瘤药学, 2014. 4(4): p. 242-246. 49. Frémont, L., Biological effects of resveratrol. Life sciences, 2000. 66(8): p. 663-673. 50. Bishayee, A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prevention Research, 2009. 2(5): p. 409-418. 51. Wu, C.-C., et al., Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta medica, 2007. 73(5): p. 439. 52. Gweon, E.J. and S.J. Kim, Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells. Oncology reports, 2013. 29(2): p. 826-834. 53. Borra, M.T., B.C. Smith, and J.M. Denu, Mechanism of human SIRT1 activation by resveratrol. Journal of Biological Chemistry, 2005. 280(17): p. 17187-17195. 54. Wolfe, B., R. Gandhi, and T. Rajah, Effectiveness of Resveratrol on Metastasis: A Review. 55. Sharma, A. and H. Gupta, Quercetin-A Flavanoid. Chronicles of Young Scientists, 2010. 1(1): p. 10. 56. Materska, M., Quercetin and its derivatives: chemical structure and bioactivity-a review. Polish Journal of Food and Nutrition Sciences, 2008. 58(4). 57. Guardia, T., et al., Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. Il farmaco, 2001. 56(9): p. 683-687. 58. Ranganathan, S., D. Halagowder, and N.D. Sivasithambaram, Quercetin Suppresses Twist to Induce Apoptosis in MCF-7 Breast Cancer Cells. PloS one, 2015. 10(10): p. e0141370. 59. Orihuela-Campos, R.C., et al., Biological impacts of resveratrol, quercetin, and N-acetylcysteine on oxidative stress in human gingival fibroblasts. Journal of clinical biochemistry and nutrition, 2015. 56(3): p. 220-227. 60. Sashindran, R., et al., Evaluation of Neuroprotective Effect of Quercetin and Coenzyme Q10 in Ethanol Induced Neurotoxicity in Mice. 2015. 61. 沈芯 and 陳彥州, Quercetin inhibition of tumor invasion via suppressing PKC/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. 2008. 62. 任治宇, 脂締素透過活化 PPARα 誘發 HO-1/COX-2 的表現及對肝細胞鐵過度沉載之保護機制. 2009. 63. Millipore(默克密理博)-蛋白轉漬手冊, M.; Available from: http://www.ebiotrade.com/newsf/2014-7/201478174350393.htm. 64. Detection, I.t.C.W.; Available from: https://www.licor.com/bio/applications/chemiluminescent_western_blot/. 65. 張書寧, Resveratrol 抑制人類乳腺癌細胞株 MDA-MB-231 的生長, 移行和侵襲能力. 2010. 66. Tang, F.Y., et al., Resveratrol inhibits migration and invasion of human breast‐cancer cells. Molecular nutrition & food research, 2008. 52(6): p. 683-691. 67. Shih, C.-W. and H.-C. Lee, Study on Resveratrol-induced Changes in Mitochondrial Mass and Function with Growth Inhibition of Human Breast Cancer Cells. 68. Buhrmann, C., et al., Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. Nutrients, 2016. 8(3): p. 145. 69. Carter, L.G., J.A. D'Orazio, and K.J. Pearson, Resveratrol and cancer: focus on in vivo evidence. Endocrine-related cancer, 2014. 21(3): p. R209-R225. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50094 | - |
| dc.description.abstract | 大部分多酚化合物都有保護正常細胞和減少腫瘤生長的作用,然而不同類型的多酚化合物的作用機制可能不一樣。而槲皮素(Quercetin,Qu)是類黃酮型的多酚化合物,可從多種天然植物以及食物中獲取。因為目前槲皮素對於調控乳腺癌的侵襲效果尚不明確。所以本論文選用與槲皮素性質最相近的白藜蘆醇(二苯二烯型的多酚化合物)作為對照組,來觀察比較槲皮素對人類乳腺癌細胞株MCF-7轉移能力的影響,並探討槲皮素影響轉移的機制。
實驗結果如下:(1)傷口癒合試驗結果顯示:乳腺癌細胞株MCF-7經槲皮素和白藜蘆醇(10,20,40,80,100μM)作用24或48小時後,發現槲皮素和白藜蘆醇皆有抑制傷口癒合的能力,且在統計學上有明顯的差異,並隨著藥物濃度的增加,抑制的能力則越強,此顯示兩種藥物對人類乳腺癌細胞株MCF-7的遷移能力皆有抑制效果。此外,有文獻指出MMP-9參與乳癌的侵襲和轉移,為了進一步探討藥物對乳腺癌細胞株MCF-7的MMP-9蛋白是否有影響,我們以西方墨點法試驗來觀察。(2)西方墨點法試驗結果顯示:藥物濃度為40μM的槲皮素和白藜蘆醇對人類乳腺癌細胞株MCF-7的MMP-9蛋白皆有下調的趨勢。又因為有文獻指出,白藜蘆醇可透過上調Sirt-1蛋白表達量來調控不同的信號通路,以發揮多種生物學功能,進而調控癌症的侵襲及轉移。因此我們也觀察了藥物對人類乳腺癌細胞株MCF-7的Sirt-1蛋白之影響,發現槲皮素和白藜蘆醇都會讓Sirt-1蛋白的表現量增加。(3)細胞遷移試驗和細胞侵襲試驗結果顯示:為了證明槲皮素和白藜蘆醇調控的MMP-9蛋白,即可使人類乳腺癌細胞株MCF-7轉移能力下降,我們採用此兩種體外細胞試驗來輔佐證明。發現槲皮素和白藜蘆醇確實可以抑制人類乳腺癌細胞株MCF-7的遷移和侵襲。另外我們也發現人類乳腺癌細胞株MDA-MB-231經槲皮素和白藜蘆醇(40μM)作用6小時對細胞遷移有顯著的抑制效果。而人類乳腺癌細胞株MDA-MB-231經槲皮素和白藜蘆醇(40μM)作用24小時對細胞侵襲亦有顯著的抑制效果。(4)細胞增殖試驗結果顯示:槲皮素和白藜蘆醇(40μM)皆能抑制人類乳腺癌細胞株MCF-7的細胞增殖。 綜合以上結果顯示:槲皮素能透過下調人類乳腺癌細胞株MCF-7的MMP-9蛋白表現量,來抑制人類乳腺癌細胞株MCF-7的遷移和侵襲。另一方面,槲皮素也可以上調人類乳腺癌細胞株MCF-7的Sirt-1蛋白表現量。因此我們可以推斷,槲皮素有可能與白藜蘆醇相似,透過上調Sirt-1蛋白表現量來抑制人類乳腺癌細胞株MCF-7的遷移和侵襲。此外,槲皮素亦能抑制轉移能力較強的人類乳腺癌細胞株MDA-MB-231的遷移和侵襲。 | zh_TW |
| dc.description.abstract | Most of polyphenol compounds have ability to protect normal cells and reduce tumor growth. Different types of polyphenols might have different mechanisms. Quercetin (Qu), which can be extracted from various natural plants and foods, is known as a flavonoid-type polyphenol. However, the effect of regulation of Quercetin on mammary cancer is still unclear. In this study, the mechanism of Quercetin’s influence on metastasis ability of MCF-7 was investigated. In order to observe and compare the effect on metastasis of MCF-7, Resveratrol, a stilbenes-type polyphenol compound with qualities most similar to Quercetin, was chosen as the control group in comparison.
The results show below: (1) In wound healing assay, both Quercetin and Resveratrol (10, 20, 40, 80 100 μM) have ability of inhibition on wound healing of MCF-7 after reacting 24 or 48 hours with a significant sifference. Along with the increase of the concentration of the agents, the inhibiting ability increases, showing that both Quercetin and Resveratrol have effect on inhibition of metastasis of MCF-7. In addition, since previous studies proposed that MMP-9 involved in invasion and metastasis of mammary cancer, we did a further investigation on whether MMP-9 of MCF-7 was influenced by medicine with West blot assay. (2) The result of Western blot assay shows MMP-9 was down-regulated both in the condition of 40 μM of Quercetin and Resveratrol. Furthermore, studies also proposed that Resveratrol, by up-regulating expressing quantity of Sirt-1, could regulate different signal paths to work biologically on regulating invasion and metastasis of cancers. For this reason, we also observed the effect of the medicine on Sirt-1 of MCF-7, and discovered both Quercetin and Resveratrol have influence on increasing the expressing quantity of Sirt-1. (3) In cell migration assay and cell invasion assay, in order to confirm that Quercetin and Resveratrol can reduce the ability of metastasis by regulating MMP-9, we did examination on two in vitro cell lines. It was realized beyond and doubt that Quercetin and Resveratrol can inhibit the invasion and metastasis of MCF-7. On the other hand, Quercetin and Resveratrol (40 μM) inhibited the metastasis of MDA-MB-231 in 6-hour reaction and the invasion of MDA-MB-231 in 24-hour reaction significantly as well. (4) The result of cell proliferation assay shows both Quercetin and Resveratrol (40 μM) can inhibit cell proliferation of human breast cancer cell line MCF-7. According to the results of our experiments, on the one hand, Quercetin can inhibit the invasion and metastasis of MCF-7 by down-regulating the expressing quantity of MMP-9. On the other hand, Quercetin can up-regulate the expressing quantity of Sirt-1 of MCF-7. Therefore, we can deduce that, like Resveratrol, Quercetin can inhibit the invasion and metastasis of MCF-7 by up-regulating the expressing quantity of Sirt-1. Besides, Quercetin can also inhibit the invasion and metastasis of MDA-MB-231, which was understood much powerful in metastasis. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T12:29:34Z (GMT). No. of bitstreams: 1 ntu-105-R02543043-1.pdf: 3932590 bytes, checksum: 399c55660a87252cab007bf62fcaf8dc (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 誌謝 ii
中文摘要 iii ABSTRACT v CONTENTS vii LIST OF FIGURES x LIST OF TABLES x Chapter 1 前言(Introduction) 1 1.1 乳癌 1 1.1.1 乳癌簡介 1 1.1.2 乳癌病理 2 1.1.3 乳癌分期 3 1.1.4 乳癌分類 3 1.1.5 轉移(Metastasis) 5 1.1.6 乳癌預後 8 1.1.7 乳癌治療 8 1.2 蛋白 10 1.2.1 基質金屬蛋白酶家族(Matrix metalloproteinases,MMPs) 10 1.2.2 沉默信息調節因子2蛋白家族(Silent information regulator 2(Sir2) proteins,Sirtuins) 12 1.4 藥 14 1.3.1 多酚(Polyphenols) 14 1.3.2 白藜蘆醇(Resveratrol) 15 1.3.3 槲皮素(Quercetin) 16 1.4 研究目的 18 Chapter 2 材料與方法(Materials and methods) 19 2.1 實驗設備及材料 19 2.1.1 實驗細胞 19 2.1.2 實驗器材 19 2.1.3 實驗試劑及化學藥品 20 2.1.4 實驗抗體 21 2.2 細胞培養(Cell Culture) 22 2.3 傷口癒合試驗(Wound healing assay) 22 2.4 西方墨點法試驗(Western blot assay) 23 2.4.1 細胞總蛋白質萃取 23 2.4.2 蛋白質定量 23 2.4.3 SDS-PAGE製作 24 2.4.4 蛋白質電泳分離 25 2.4.5 西方墨點法(Western blot) 25 2.5 細胞遷移試驗(Cell migration assay) 27 2.6 細胞侵襲試驗(Cell invasion assay) 27 2.7 細胞增殖試驗(Cell proliferation assay) 28 Chapter 3 實驗結果(Results) 29 3.1 細胞型態 29 3.2 傷口癒合試驗(Wound healing assay) 32 3.3 西方墨點法試驗(Western blot assay) 38 3.4 細胞遷移試驗(Cell migration assay) 42 3.5 細胞侵襲試驗(Cell invasion assay) 44 3.6 細胞增殖試驗(Cell proliferation assay) 46 Chapter 4 實驗討論(Discussion) 47 4.1 白藜蘆醇和槲皮素對人類乳腺癌細胞株MCF-7的細胞型態之影響 47 4.2 白藜蘆醇和槲皮素對人類乳癌細胞株MCF-7傷口癒合的影響 47 4.3 白藜蘆醇和槲皮素對人類乳腺癌細胞株MCF-7的MMP-9蛋白以及Sirt-1蛋白的調控 48 4.4 白藜蘆醇和槲皮素對人類乳癌細胞株MCF-7細胞遷移和細胞侵襲的影響 49 4.5 白藜蘆醇和槲皮素對人類乳癌細胞株MCF-7細胞遷增殖的影響 49 Chapter 5 結論與展望(Conclusion and Perspective) 50 5.1 結論 50 5.2 未來展望 51 REFERENCE 52 | |
| dc.language.iso | zh-TW | |
| dc.subject | 槲皮素 | zh_TW |
| dc.subject | MCF-7 | zh_TW |
| dc.subject | 乳癌轉移 | zh_TW |
| dc.subject | 白藜蘆醇 | zh_TW |
| dc.subject | Sirt-1 | zh_TW |
| dc.subject | MMP-9 | zh_TW |
| dc.subject | MCF-7 | zh_TW |
| dc.subject | 乳癌轉移 | zh_TW |
| dc.subject | 白藜蘆醇 | zh_TW |
| dc.subject | 槲皮素 | zh_TW |
| dc.subject | Sirt-1 | zh_TW |
| dc.subject | MMP-9 | zh_TW |
| dc.subject | Breast Metastasis | en |
| dc.subject | MCF-7 | en |
| dc.subject | MMP-9 | en |
| dc.subject | MMP-9 | en |
| dc.subject | Resveratrol | en |
| dc.subject | Sirt-1 | en |
| dc.subject | Quercetin | en |
| dc.subject | MCF-7 | en |
| dc.subject | Breast Metastasis | en |
| dc.subject | Resveratrol | en |
| dc.subject | Quercetin | en |
| dc.subject | Sirt-1 | en |
| dc.title | 槲皮素和白藜蘆醇調控Sirt-1來抑制人類乳腺癌細胞(MCF-7)的轉移機制之探討 | zh_TW |
| dc.title | Investigation of inhibitory effects of quercetin and resveratrol through Sirt-1 regulation in Human breast cancer cell(MCF-7) metastasis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 徐立中,張家歐 | |
| dc.subject.keyword | MCF-7,乳癌轉移,白藜蘆醇,槲皮素,Sirt-1,MMP-9, | zh_TW |
| dc.subject.keyword | MCF-7,Breast Metastasis,Resveratrol,Quercetin,Sirt-1,MMP-9, | en |
| dc.relation.page | 55 | |
| dc.identifier.doi | 10.6342/NTU201601955 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-08-05 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 應用力學研究所 | zh_TW |
| 顯示於系所單位: | 應用力學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 未授權公開取用 | 3.84 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
